Hercules Capital, Inc. (0J4M.L)
| Previous close | 19.25 |
| Open | 19.64 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 19.23 - 19.77 |
| 52-week range | 11.48 - 19.77 |
| Volume | |
| Avg. volume | 3,126 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 0.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Hercules Capital Reports First Quarter 2024 Financial Results
SAN MATEO, Calif., May 02, 2024--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the first quarter ended March 31, 2024. The earnings release can be accessed at Hercules’ Investor Relations website at https://investor.htgc.com/finan
- Business Wire
Hercules Capital Declares a Total Cash Distribution of $0.48 per Share for the First Quarter 2024
SAN MATEO, Calif., April 30, 2024--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a first quarter 2024 total cash distribution of $0.48 per share. The following shows the key dates of the first quarter 2024 dis
- PR Newswire
SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, today announces it has entered into a $35m loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules").
